《肢端肥大症诊治中国专家共识(2020版)》系列解读之三:肢端肥大症的药物治疗  

Series interpretation to Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020)(Part 3):Pharmaceutical treatments

作　　者：李海[1] 李延兵[1] Li Hai;Li Yanbing(Department of Endocrinology,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院内分泌科,广州510080

出　　处：《中华内分泌代谢杂志》2021年第5期425-428,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：肢端肥大症作为一种隐匿起病的内分泌代谢疾病,其诊断和治疗的延误使得并发症发生率明显增加,早期发现、早期诊断及治疗对于肢端肥大症患者的预后极为重要。《肢端肥大症诊治中国专家共识(2020版)》利用近年大量的循证医学证据,规范了肢端肥大症的诊断和治疗策略。在非手术治疗部分,根据药物的种类,对肢端肥大症药物治疗的适应证和选择、使用方法及注意事项等作出具体的推荐。希望新共识能够进一步指导和规范肢端肥大症的临床管理。Acromegaly is an endocrine and metabolic disease with insidious onset.Delays in its diagnosis and treatment significantly increase the incidence of complications.Early detection,diagnosis,and treatment are extremely important for the prognosis of patients with acromegaly.Based on a large quantity of evidence in recent years,Chinese Expert Consensus on the Diagnosis and Treatment of Acromegaly(2020)has standardized the diagnosis and the treatment strategies of acromegaly.In the non-surgical treatment section,according to the categories of drugs used to treat acromegaly,the indications,selection,administration,dosage and precautions of pharmaceutical treatment have been clarified with specific recommendations.It is hoped that the new consensus can further guide and standardize the clinical management of acromegaly.

关 键 词：肢端肥大症 药物 共识 解读 

分 类 号：R584.11[医药卫生—内分泌]